The Cannabinoid Pivot: Why CBG is Gaining Interest in Sports Science

Market Performance Data

• CBD (Cannabidiol): Supports systemic inflammation management and cortisol regulation.
• CBG (Cannabigerol): May support localized muscle relaxation and GABA-mediated tension relief.
• Humulene: Supports analgesic activity and may assist with appetite regulation, which can be helpful for athletes on caloric restrictions.
• Nano-Emulsification: Research suggests this may increase bioavailability from 6% to over 20%, bypassing first-pass metabolism.
• Regulatory Compliance: CBD remains the only WADA-exempt cannabinoid; all other minor cannabinoids carry potential competition risk.

The Physiology of Recovery

Delayed Onset Muscle Soreness (DOMS) results from microscopic sarcomere damage and subsequent inflammatory cascades. While acute inflammation initiates muscle hypertrophy, chronic oxidative stress may stall connective tissue repair. The Endocannabinoid System (ECS) maintains homeostasis by modulating these inflammatory signals. Cannabinoids may function as exogenous support for the ECS "dimmer switch."

CBG vs. CBD: Receptor Affinity and Mechanism

Industry interest is shifting toward CBG for physical recovery due to its unique binding profile.

CBD: The Systemic Modulator

CBD does not bind directly to CB1 or CB2 receptors. It inhibits the FAAH enzyme, which may increase levels of the endogenous cannabinoid anandamide.

• Primary Utility: Global inflammation management.
• Psychological Impact: May support relaxation and improved sleep architecture.
• Limitation: Low direct affinity for cannabinoid receptors makes it a passive modulator.

CBG: The Neuromuscular Specialist

CBG binds directly to both CB1 and CB2 receptors. It may inhibit the uptake of GABA, the neurotransmitter associated with muscle relaxation.

• Primary Utility: Support for muscle spasm management.
• Neuro-Efficiency: CBG acts as an alpha-2 adrenoceptor agonist. This may trigger a transition from the Sympathetic (Fight or Flight) to the Parasympathetic (Rest and Digest) nervous system.
• Gut Health: CBG shows potential in managing GI inflammation, which can be an issue for athletes on high-protein diets.

Terpene Optimization: The Humulene Factor

Terpenes dictate the "direction" of cannabinoid activity. Caryophyllene is a known anti-inflammatory that binds to CB2 receptors. Humulene provides a potential advantage for weight-conscious athletes.

Most cannabis derivatives stimulate appetite through the Ghrelin pathway. Humulene may act as an anorectic. It may suppress hunger while providing localized analgesic support. Utilizing high-humulene profiles allows for inflammation management without disrupting strict nutritional protocols.

Delivery Systems: From Salves to Transdermals

Standard topical balms sit on the epidermis. They provide surface-level relief but may fail to reach deep muscle tissue. Transdermal delivery systems use penetration enhancers like oleic acid to assist in bypassing the skin barrier.

Nano-emulsified tinctures represent current developments in delivery technology. These water-soluble formulations reduce particle size to under 100nm.

• Traditional Oil Onset: 60–90 minutes.
• Nano-Cationic Onset: 15–20 minutes. Rapid onset may be beneficial during the post-workout recovery window.

Compliance and Professional Standards

The World Anti-Doping Agency (WADA) allows CBD isolate. All other cannabinoids, including CBG, CBN, and THC, remain on the prohibited list for in-competition use.

Market transparency is often lacking in "full-spectrum" labeling. Athletes in tested environments should utilize Third-Party Lab Tested CBD Isolate to avoid cross-contamination. Minor cannabinoids like CBG are currently reserved for off-season recovery or non-tested populations.

The Optimized Recovery Protocol

1. Intra-Workout: 10mg Nano-CBD to support cortisol stabilization.
2. Immediate Post-Workout: 20mg CBD / 10mg CBG sublingual tincture for rapid GABA inhibition.
3. Targeted Relief: Transdermal 1:1 CBD/CBG patch applied to the primary muscle group.
4. Sleep Cycle: 20mg CBD paired with 5mg CBN (Cannabinol) to support Stage 3 Deep Sleep and HGH release.

Integrating a 1:1 CBD to CBG ratio provides a multi-phase approach to recovery. CBD manages the systemic inflammatory load while CBG addresses specific neuromuscular tension.

---

Legal Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always seek the advice of a physician regarding a medical condition. Efficacy has not been confirmed by FDA-approved research. Check your local laws regarding cannabis and terpene use.

Sources

1. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Claro E, Izzo AA. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 85(9):1306-16. PubMed

2. Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM. (2016). Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. Psychopharmacology (Berl). 233(19-20):3603-13. PubMed

3. Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163(7):1344-64. PubMed

4. Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, Westlund KN. (2016). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 20(6):936-48. PubMed

5. Formato M, Crescente G, Scognamiglio M, Fiorentino A, Pecoraro MT, Piccolella S, Pacifico S. (2020). (‒)-Cannabidiolic acid, a still overlooked bioactive compound: an exploratory review of the literature. Molecules. 25(11):2638. PubMed